Volition Hosts KOL Roundtable on Sepsis
VolitionRx (NYSE AMERICAN: VNRX) hosted a Key Opinion Leader (KOL) roundtable in Paris to explore the potential of its Nu.Q® NETs technology in sepsis management. The event, chaired by Professor Djillali Annane, brought together leading sepsis experts worldwide. Discussions revealed that Nu.Q® NETs could potentially predict organ failure, such as acute kidney injury, in patients with infection, enhancing sepsis management.
Nu.Q® NETs quantifies circulating H3.1 nucleosomes in the bloodstream, a marker for Neutrophil Extracellular Traps (NETs). While NETs are important for immune response, elevated levels can lead to tissue damage and, in severe cases, sepsis and organ failure. Volition plans to share latest findings at an upcoming symposium at ESICM in Barcelona on October 7, 2024.
VolitionRx (NYSE AMERICAN: VNRX) ha organizzato un tavolo rotondo con Key Opinion Leader (KOL) a Parigi per esplorare il potenziale della sua tecnologia Nu.Q® NETs nella gestione della sepsi. L'evento, presieduto dal Professor Djillali Annane, ha riunito esperti di sepsi di fama mondiale. Le discussioni hanno rivelato che Nu.Q® NETs potrebbe potenzialmente prevedere il fallimento degli organi, come ad esempio l'insufficienza renale acuta, nei pazienti con infezione, migliorando la gestione della sepsi.
Nu.Q® NETs quantifica i nucleosomi H3.1 circolanti nel flusso sanguigno, un marcatore per le Neutrophil Extracellular Traps (NETs). Sebbene i NETs siano importanti per la risposta immunitaria, livelli elevati possono portare a danni ai tessuti e, nei casi gravi, a sepsi e insufficienza d'organo. Volition prevede di condividere gli ultimi risultati in un prossimo simposio all'ESICM di Barcellona il 7 ottobre 2024.
VolitionRx (NYSE AMERICAN: VNRX) organizó una mesa redonda con Líderes de Opinión Clave (KOL) en París para explorar el potencial de su tecnología Nu.Q® NETs en la gestión de la sepsis. El evento, presidido por el Profesor Djillali Annane, reunió a destacados expertos en sepsis de todo el mundo. Las discusiones revelaron que Nu.Q® NETs podría potencialmente predecir la falla orgánica, como la lesión renal aguda, en pacientes con infección, mejorando así la gestión de la sepsis.
Nu.Q® NETs cuantifica los nucleosomas H3.1 circulantes en el torrente sanguíneo, un marcador para las Neutrophil Extracellular Traps (NETs). Si bien los NETs son importantes para la respuesta inmune, los niveles elevados pueden provocar daños en los tejidos y, en casos severos, sepsis y falla orgánica. Volition planea compartir los últimos hallazgos en un próximo simposio en la ESICM en Barcelona el 7 de octubre de 2024.
VolitionRx (NYSE AMERICAN: VNRX)는 파리에서 중대한 의견 리더(KOL) 라운드테이블을 개최하여 자사의 Nu.Q® NETs 기술이 패혈증 관리에 미칠 잠재력을 탐구했습니다. 이 행사에는 Djillali Annane 교수님이 의장을 맡아 전 세계의 주요 패혈증 전문가들이 모였습니다. 논의 결과, Nu.Q® NETs가 감염 환자에서 조직 손실 예측, 예를 들어 급성 신장 손상 등을 예측할 수 있을 것으로 보이며, 패혈증 관리 개선에 기여할 수 있음을 밝혔습니다.
Nu.Q® NETs는 혈류에서 순환하는 H3.1 뉴클레오솜을 정량화하며, 이는 호중구 세포외 그물(NETs)에 대한 마커입니다. NETs는 면역 반응에 중요하지만, 높은 수준은 조직 손상을 초래할 수 있으며 심각한 경우 패혈증 및 장기 부전으로 이어질 수 있습니다. Volition은 2024년 10월 7일 바르셀로나에서 열리는 ESICM 심포지엄에서 최신 연구 결과를 공유할 계획입니다.
VolitionRx (NYSE AMERICAN: VNRX) a organisé une table ronde avec des Leaders d'Opinion Clé (KOL) à Paris pour explorer le potentiel de sa technologie Nu.Q® NETs dans la gestion de la sepsis. L'événement, présidé par le Professeur Djillali Annane, a réuni des experts en sepsis de premier plan du monde entier. Les discussions ont révélé que Nu.Q® NETs pourrait potentiellement prévoir l'échec organique, comme des lésions rénales aiguës, chez les patients infectés, améliorant ainsi la gestion de la sepsis.
Nu.Q® NETs quantifie les nucléosomes H3.1 circulants dans le sang, un marqueur des Neutrophil Extracellular Traps (NETs). Bien que les NETs soient importants pour la réponse immunitaire, des niveaux élevés peuvent entraîner des dommages tissulaires et, dans les cas graves, la sepsis et l'échec organique. Volition prévoit de partager les dernières découvertes lors du prochain symposium à ESICM à Barcelone le 7 octobre 2024.
VolitionRx (NYSE AMERICAN: VNRX) veranstaltete ein Roundtable-Meeting mit Key Opinion Leader (KOL) in Paris, um das Potenzial seiner Nu.Q® NETs-Technologie im Sepsis-Management zu erörtern. Die Veranstaltung, geleitet von Professor Djillali Annane, versammelte führende Sepsis-Experten aus aller Welt. Die Diskussionen zeigten, dass Nu.Q® NETs potenziell Organsversagen vorhersagen könnte, wie beispielsweise akute Nierenverletzung, bei Patienten mit Infektionen, was das Sepsis-Management verbessert.
Nu.Q® NETs quantifiziert zirkulierende H3.1-Nukleosomen im Blutkreislauf, einen Marker für Neutrophil Extracellular Traps (NETs). Während NETs wichtig für die Immunantwort sind, können erhöhte Werte zu Gewebeschäden führen und in schweren Fällen zu Sepsis und Organversagen. Volition plant, die neuesten Erkenntnisse auf einem bevorstehenden Symposium bei der ESICM in Barcelona am 7. Oktober 2024 zu teilen.
- Potential of Nu.Q® NETs technology to predict organ failure in sepsis patients
- Collaboration with key opinion leaders and centers of excellence worldwide
- Upcoming satellite symposium at ESICM in Barcelona to share latest findings
- None.
The roundtable event was chaired by Professor Djillali Annane, Professor of Medicine at University Paris Saclay-UVSQ.
Professor Annane, said: "The need for improvements in sepsis management and patient outcomes is clear. Sepsis kills over 11 million people worldwide each year, and approximately half of those who survive the disease are left with devastating, long-term physical and psychological effects. Early detection and management of sepsis has the potential to reduce mortality and improve the quality of life of survivors.
"We brought together experts in sepsis from across the globe to share research findings from several large independent studies, and consider how Volition's Nu.Q® NETs technology could be introduced in clinical practice.
"It was clear from our roundtable discussion and confidential data review that Nu.Q® NETs has the potential to predict organ failure, for example, acute kidney injury in patients with infection and therefore could be used to enhance sepsis management."
Nu.Q® NETs, Volition's nucleosome quantification technology, is a simple, low-cost, accessible test that quantifies an individual's level of circulating H3.1 nucleosomes in the bloodstream, a surrogate marker for Neutrophil Extracellular Traps (NETs). Although NETs play a critical role in our normal immune response, elevated levels of NETs can lead to tissue damage, and in severe cases, sepsis, organ failure and death.
Dr Andrew Retter, Chief Medical Officer at Volition, said: "Volition is collaborating closely with KOLs and centers of excellence worldwide, and we are delighted to have hosted such an esteemed roundtable event. With a range of publications pending, we look forward to sharing latest findings at our upcoming satellite symposium, taking place at ESICM in
Chaired by Professor Djillali Annane Volition's KOL event comprised:
- Professor Derek Angus, Professor and Chair of the Critical Care Medicine Department at the University of
Pittsburgh . Professor Angus is a world-renowned clinical, translational and health services researcher. (Partial attendance; virtual) - Professor Michael Bauer, Professor and Chair of the Department of Anaesthesiology and Intensive Care Medicine at Jena University Hospital,
Germany . - Dr. Lieuwe Bos is Principal Investigator within the Intensive Care department at Amsterdam UMC. He is also an associate professor at the University of
Amsterdam . (Partial attendance) - Professor Luc de Chaisemartin is Professor of Immunology at Paris-Cité University, and Head of the Biological Immunology Department at Bichat Hospital,
Paris . - Dr. Charles Dehout is an attending physician at Erasmus Hospital in
Brussels , specializing in internal medicine and intensive care. - Professor Evangelos J. Giamarellos-Bourboulis, National and Kapodistrian University of
Athens, Greece and Chair of the European Sepsis Alliance. - Dr. Caroline Neumann is Caroline Neumann is a Senior Consultant in Intensive Care Medicine at Jena University Hospital,
Germany . - Dr. Andrew Retter, Clinical Lead in Critical Care Medicine, ECMO and Thrombosis, and Chief Medical Officer at Volition.
- Professor Mervyn Singer OBE, University College
London, UK . Co-chair of the Sepsis-3 Definitions International Task Force; past-chair, International Sepsis Forum; Sepsis Topic Adviser to NICE; Emeritus NIHR Senior Investigator.
Notes
- Sepsis arises when the body's response to an infection injures its own tissues and organs. It may lead to shock, multi-organ failure, and death – especially if not recognized early and treated promptly. (Global Sepsis Alliance - World Sepsis Day website)
- Sepsis is the number one cause of death in hospitals worldwide and accounts for at least 11 million deaths per year.
- September is Sepsis Awareness Month and World Sepsis Day takes place on Friday 13th September 2024.
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients, but also improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition, mediarelations@volition.com +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to the timing, completion, success and delivery of data from clinical studies, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this press release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
Photo: https://mma.prnewswire.com/media/2502647/VolitionRx.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/volition-hosts-kol-roundtable-on-sepsis-302244942.html
SOURCE VolitionRx Limited
FAQ
What is the potential application of Volition's Nu.Q® NETs technology in sepsis management?
When and where will Volition share the latest findings on Nu.Q® NETs technology?
What does Volition's Nu.Q® NETs technology measure?
Who chaired the KOL roundtable event hosted by Volition (VNRX) on sepsis?
